Literature DB >> 3674580

Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not.

J I Dutoit1, C M Salome, A J Woolcock.   

Abstract

In a double-blind crossover study, we compared the relative effects of inhaled beclomethasone dipropionate (BDP) 800 micrograms per day and oral theophylline on the severity of bronchial hyperresponsiveness (BHR) to histamine. Daily doses of theophylline were sufficient to keep serum levels between 55 and 110 mumol/L. The subjects were 26 patients with severe asthma whose symptoms were inadequately controlled by regular treatment with inhaled salbutamol. The severity of BHR improved within 3 wk in the group treated with BDP, whereas no change occurred in the group treated with theophylline. There were no significant changes in FEV1 in either group during the study. When BDP was changed to theophylline there was a deterioration in BHR. Aerosol steroids, rather than theophylline, are the treatment of choice when reduction in the severity of BHR is the aim of treatment in patients with severe asthma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674580     DOI: 10.1164/ajrccm/136.5.1174

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

Review 1.  Management of asthma in pre-school children.

Authors:  T P McCarthy; W Lenney
Journal:  Br J Gen Pract       Date:  1992-10       Impact factor: 5.386

Review 2.  Asthma: the pulse is not the paradox.

Authors:  M H Williams
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 4.  Management of chronic airway obstruction: theophylline--is it still necessary?

Authors:  D Ukena; G W Sybrecht
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model.

Authors:  A Z El-Hashim; K H Banner; W Paul; C P Page
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Do bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness?

Authors:  C P van Schayck; C L van Herwaarden
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

7.  Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast.

Authors:  L Jayaram; E Pizzichini; C Lemière; S F P Man; A Cartier; F E Hargreave; M M M Pizzichini
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

8.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.

Authors:  D R Taylor; M R Sears; G P Herbison; E M Flannery; C G Print; D C Lake; D M Yates; M K Lucas; Q Li
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

Review 9.  Physiological changes due to age. Implications for respiratory drug therapy.

Authors:  J F Morris
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 10.  Theophylline. Current thoughts on the risks and benefits of its use in asthma.

Authors:  S S Nasser; P J Rees
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.